Investigation Questions Drug's Approval for Agitation in AD

The agency defended approval of brexpiprazole (Rexulti) for the treatment of agitation, saying the antipsychotic fills an unmet medical need.

Related Keywords

Pennsylvania ,United States ,California ,Mansfield ,Lon Schneider ,Rajesh Narendran ,Los Angeles ,Robert Whitaker ,Lundbeck ,Alzheimer Association ,University Of Pittsburgh ,Alliance For Aging Research ,Drug Administration ,Medicaid Services ,Us Centers For Medicare ,Medscape Medical ,Cohen Mansfield Agitation Inventory ,Information Act ,Southern California ,Keck School ,Drug Fills Unmet ,Medscape Medical News ,Aging Research ,Leaders Engaged ,Alzheimers Disease ,Lzheimer Disease ,Antipsychotics ,Neuroleptics ,Neuroleptic Drugs ,Agitation ,Dementia ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Adverse Effects ,Side Effects ,Medicare ,Nursing Homes ,Patient Safety ,